Moberg Pharma

Moberg Pharma’s Nomination Committee ahead of the Annual General Meeting for the fiscal year January – December 2024 comprises:

• Mattias Klintemar, appointed by Östersjöstiftelsen
• Styrbjörn Zachau
• Kerstin Valinder Strinnholm, Chairman of the Board

Together, the Nomination Committee represents 9.4 percent of the shares in Moberg Pharma as of September 30^th, 2024.

The Nomination Committee shall submit proposals for the fiscal year January – December 2024 by the Annual General Meeting pertaining to the election of Chairman of the Board, fees and composition of the Board, auditors’ fees and the election of auditors.

The Annual General Meeting for the fiscal year January – December 2024 will be held on May 22^nd, 2025.

Shareholders wishing to submit proposals to Moberg Pharma’s Nomination Committee can do so by e-mail to info@mobergpharma.se by April 3^rd, 2025.

About this information
The information was submitted for publication, through the agency of the contact person set out below, at 8.30 a.m. CET on November 8^th, 2024.

For additional information, please contact:
Anna Ljung, CEO, Phone: +46 8 522 307 01, e-mail: anna.ljung@mobergpharma.se

About Moberg Pharma, www.mobergpharma.com
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company’s drug MOB-015 is a novel topical treatment for onychomycosis (nail fungus) with market approval in 13 EU countries. MOB-015 is sold in Sweden under the brand name Terclara^® and is available at all pharmacy chains. Phase 3 clinical trials for MOB-015 involving more than 800 patients indicate that the product has the potential to become the future market leader in onychomycosis. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada. Moberg Pharma is headquartered in Stockholm and the company's shares are listed under Small Cap on Nasdaq Stockholm (OMX: MOB).